Oxytocin-a multifunctional analgesic for chronic deep tissue pain

Current Pharmaceutical Design

Volumn 21, Issue 7, 2015, Pages 906-913

  Goodin, Burel R ^a   Ness, Timothy J ^a   Robbins, Meredith T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Analgesics; Anxiolytics; Musculoskeletal pain; Nociception; Oxytocin; Visceral pain

Indexed keywords

OXYTOCIN; OXYTOCIN RECEPTOR; PLACEBO; ANALGESIC AGENT; OXYTOCIC AGENT;

ABDOMINAL PAIN; ANALGESIA; ANALGESIC ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ARTICLE; BLADDER DISTENSION; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CONTINUOUS INFUSION; DEPRESSION; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; FIBROMYALGIA; HUMAN; INHIBITORY POSTSYNAPTIC POTENTIAL; INTERSTITIAL CYSTITIS; LONG TERM POTENTIATION; LOW BACK PAIN; MOOD; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; OXYTOCIN BLOOD LEVEL; PAIN SEVERITY; PAIN THRESHOLD; PAW EDEMA; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; SOMATOSENSORY SYSTEM; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL; TRANQUILIZING ACTIVITY; ANIMAL; NOCICEPTIVE PAIN; PROCEDURES; PSYCHOLOGY;

ANALGESICS; ANIMALS; CHRONIC PAIN; HUMANS; NOCICEPTIVE PAIN; OXYTOCICS; OXYTOCIN; PAIN MANAGEMENT;

EID: 84925882340     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141027111843     Document Type: Article

References (157)

1. [1] Committee on Advancing Pain Research, Care, and Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. National Academies Press, 2011.
2. [2] Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope and impact of spinal pain. Pain Physician 2009; 12: E35-70.
3. [3] Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002; 18: 355-65.
4. [4] Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-9.
5. [5] Gaskin DL, Richard P. The economic costs of pain in the United States. J Pain 2012; 13: 715-24.
6. [6] Chou R, Fanciullo GJ, Fine PG, et al. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
7. [7] Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain physician 2008; 11(2 Suppl): S105-20.
8. [8] Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Canadian Med Assoc J 2006; 174(11): 1589-94.
9. [9] Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000; 7: 257-77.
10. [10] Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26: 30-6.
11. [11] Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. 2008 Drugs; 68: 2611-32.
12. [12] Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD001133. DOI: 10.1002/14651858.CD001133.pub3.
13. [13] Christoph T, Grünweller A, Mika J, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun 2006; 350: 238-43.
14. [14] Neugebauer V. Metabotropic glutamate receptors-important modulators of nociception and pain behavior. Pain 2002; 98: 1-8.
15. [15] Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action. J Pain 2000; 1: 2-14.
16. [16] Vanegas H, Schaible H-G. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgeisa, and allodynia. Pain 2000; 85: 9-18.
17. [17] Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium channels and pain pathways. Dev Biol 2004; 61: 55-71.
18. [18] Juif J-E and Poisbeau P. Neurohumoral effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats. Pain 2013; 154: 1449-56.
19. [19] Murphy D, Konopacka A, Hindmarch C, et al. The hypothalamicneurophypohyseal system: from genome to physiology. J Neuroendocrinol. 2012; 24: 539-53.
20. [20] Rash JA, Aguirre-Camacho A and Campbell TS. Oxytocin and pain: a systematic review and syntesis of findings. Clin J Pain. In press 2013
21. [21] Stoop R. Neuromodulation by oxytocin and vasopressin. Neuron 2012; 76: 142-59
22. [22] Viero C, Shibuya I, Kitamura N, et al. Oxytocin: crossing the bridge between basic science and pharmacotherapy CNS Neurosci Ther 2010; 16: e138-56.
23. [23] Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ and Neumann ID. Brain oxytocin correlates with maternal aggression: link to anxiety. J Neurosci 2005; 25: 6807-15.
24. [24] Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 2003; 54: 1389-98.
25. [25] Heinrichs M, Meinlschmidt G, Neumann I, et al. Effects of suckling on hypothalamic-pituitary-adrenal axis responses to psychosocial stress in postpartum lactating women. J Clin Endocrinol Metabolism 2001; 86: 4798-804.
26. [26] Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin and affiliative behavior. Neuron 2010; 65: 768-79.
27. [27] Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005; 435: 673-6.
28. [28] Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging 2011; 3: 1169-77.
29. [29] Mah BL, van Ijzendoom MH, Smith R, Bakermans-Kranenburg MJ. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog NeuroPsychopharm Biol Psychiatry 2013; 40: 267-72.
30. [30] Mazzuca M, Minlebaev M, Shakirzyanova A, et al. Newborn analgesia mediated by oxytocin during delivery. Front Cell Neurosci 2011; 5: 3.
31. [31] Neumann ID, Torner L and Wigger A. Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats. Neurosci 2000; 95: 567-575.
32. [32] Panksepp J. Oxytocin effects on emotional processes: separation distress, social bonding, and relationships to psychiatric disorders. Ann N Y Acad Sci 1992; 652: 243-52.
33. [33] Zak PJ, Kurzban R, Matzner WT. Oxytocin is associated with human trustworthiness. Horm Behav 2005; 48: 522-7.
34. [34] Zak PJ, Stanton AA, Ahmadi S. Oxytocin increases generosity in humans. PLoS ONE 2007; 2: e1128.
35. [35] Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol. Autism 2012; 3: 16.
36. [36] MacDonald K and Feifel D. Dramatic improvement in sexual function induced by intranasal oxytocin. J Sex Med 2012; 9: 1407-10.
37. [37] Phillips WJ, Ostrovsky O, Galli RL and dickey S. Relief of acute migraine headache with intravenous oxytocin: report of two cases. J Pain Palliat Care Pharmacother 2006; 20: 25-8.
38. Modabbernia A, Rezaei F, Salehi B, et al. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: ann 8 week randomized, double-blind, placebo-controlled study. CNS Drugs 2012; epub Dec 12.
39. [39] McGregor IS and Bowen MT. Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav 2012; 61: 331-9.
40. Chapman CD, Frey WH 2nd, Craft S, et al Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2012; epub Nov 8.
41. [41] MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F and Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36: 1114-26.
42. [42] In JH, Choi JW, Jung HS, et al. Severe hypotension and water intoxication developed after an accidental oxytocin overdose in a morbidly obese patient undergoing cesarean section-a case report. Korean J Anesthesiol 2011; 60: 290-3.
43. [43] Minowa Y, Hara K and Sata T. A case of myocardial ischemia induced by oxytocin during cesarean section. Masui 2013; 62: 982-984.
44. [44] Borg J and Ohlsson B. Oxytocin prolongs the gastric emptying time in patients with diabetes mellitus and gastroparesis, but does not affect satiety or volume intake in patients with functional dyspepsia. BMC Research Notes 2012; 5: 148.
45. [45] Benoussaidh A, Mauriin Y and Rampin O. Spinal effects of oxytocin on uterinie motility in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: R446-53.
46. [46] Pandita RK, Nylen A and Andersson K-E. Oxytocini-induced stimulation and inihibition of bladder activity in normal, conscious rats-influence of nitric oxide synthase inhibition. Neurosci 1998; 85: 1113-9.
47. [47] Amico JA, Challinor SM, Cameron JL. Pattern of oxytocin concentrations in the plasma and cerebrospinal fluid of lactating rhesus monkeys (Macaca mulatta): evidence for functionally independent oxytocinergic pathways in primates. J Clin Endocrinol Metab 1990; 71: 1531-5.
48. [48] Cechetto DF, Saper CB. Neurochemical organization of the hypothalamic projection of the spinal cord in the rat. J. Comp Neurol 1988; 272: 579-604.
49. [49] Ge Y, Lundeberg T, Yu LC. Blockade effect of mu and kappa opioid antagonists on the antinociception induced by intraperiaqueductal grey injection of oxytocin in rats. Brain Res 2002; 927: 204-7.
50. [50] Reeta K, Mediratta PK, Rathi N, Jain H, Chugh C, Sharma KK. Role of kappa-and delta opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice. Regul Pept 2006; 135: 85-90.
51. [51] Rheeta KH, Mediratta PK, Rathi N, Jin H, Chugh C and Sharma KK. Role of k-and d-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain responses in mice. Reg Peptides 2006; 135: 85-90.
52. [52] Bodnar RJ, Nilaver G, Wallace MM, Badillo-Martinez D, Zimmerman EA. Pain threshold changes in rats following central injection of beta-endorphin, met-enkephalin, vasopressin or oxytocin antisera. Int J Neurosci 1984; 24: 149-60.
53. [53] Yang J, Li P, Liang JY, Pan YJ, et al. Oxytocin in the periaqueductal grey regulates nociception in the rat. Regul Pept 2011; 169: 39-42.
54. [54] Yang J, Liang JY, Li P, et al. Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides. Peptides 2011; 32: 1255-61.
55. [55] Yang J, Yang Y, Chen JM, et al. Central oxytocin enhances antinociception in the rat. Peptides 2007; 28: 1113-9.
56. [56] Yang J, Yang Y, Chen JM, Liu WY, Lin BC. Effect of hypothalamic supraoptic nucleus on acupuncture analgesia in the rat. Brain Res Bull. 2008; 75: 681-6.
57. [57] Yang J, Yang Y, Chen JM, Liu WY, Wang CH, Lin BC. Effect of oxytocin on acupuncture analgesia in the rat. Neuropeptides 2007; 41: 285-92.
58. [58] Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 2009; 65: 728-31.
59. [59] Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009; 30: 548-57.
60. [60] Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005; 30: 924-9.
61. [61] Windle R, Shanks N, Lightman SL, Ingram CD. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 1997; 138: 2829-34.
62. [62] Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433-45.
63. [63] Chapman CR, Tuckett RP, Song CH. Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain 2008; 9: 122-45.
64. [64] Raggenbass M. Vasopressin-and oxytocin-induced activity in the central nervous system: electrophysiological studies using in-vitro systems. Prog Neurobiol 2001; 64: 307-26.
65. [65] Ishak WW, Kahloon M, Fakhry H. Oxytocin role in enhancing well-being: a literature review. J Affect Disord 2011; 130: 1-9.
66. [66] Manning M, Misicka A, Olma A, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012; 24: 609-28.
67. [67] Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonist and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008; 170: 473-512.
68. [68] Caldwell JD, Mason GA, Stanley DA, et al. Effects of nonapeptide antagonists on oxytocin-and arginine-vasopressin-induced analgesia in mice. Regul Pept 1987; 18: 233-41.
69. [69] Gimpl G and Fahrenholz F. The oxytocin receptor system: structure, function and regulation. Physiol Rev 2001; 81: 629-83.
70. [70] Condes-Lara M, Martinez-Lorenzana G, Rojas-Piloni G, Rodriguez-Jimenez J. Branched oxytocinergic innervations from the paraventricular hypothalamic nuclei to superficial layers in the spinal cord. Brain Res 2007; 1160: 20-9.
71. [71] Rousselot P, Papadopoulos G, Merighi A, Poulain DA, Theodosis DT. Oxytocinergic innervation of the rat spinal cord. An electron microscopic study. Brain Res 1990; 529: 178-84.
72. [72] Puder BA, Papka RE. Distribution and origin of corticotropinreleasing factor-immunoreactive axons in the female rat lumbosacral spinal cord. J Neurosci Res 2001; 66: 1217-25.
73. [73] Reiter MK, Kremarik P, Freund-Mercier MJ, Stoeckel ME, Desaulles E, Feltz P. Localization of oxytocin binding sites in the thoracic and upper lumbar spinal cord of the adult and postnatal rat: a histoautoradiographic study. Eur J Neurosci 1994; 6: 98-104.
74. [74] Jo YH, Stoeckel ME, Freund-Mercier MJ, Schlichter R. Oxytocin modulates glutamatergic synaptic transmission between cultured neonatal spinal cord dorsal horn neurons. J Neurosci 1998; 18: 2377-86.
75. [75] Robinson DA, Wei F, Wang GD, et al. Oxytocin mediates stressinduced analgesia in adult mice. J Physiol 2002; 540(Pt 2): 593-606.
76. [76] Lee HJ, Macbeth AH, Pagani JH, Young WS, 3rd. Oxytocin: the great facilitator of life. Prog Neurobiol 2009; 88: 127-51.
77. [77] Ayar A, Ozcan M, Alcin E, et al. Oxytocin activates calcium signaling in rat sensory neurons through a protein kinase C-dependent mechanism. J Physiol Biochem 2013; epub, Aug 6, 2013.
78. [78] Hobo S, Hayashida K, Eisenach JC. Oxytocin inhibits the membrane depolarization-induced increase in intracellular calcium in capsaicin sensitive sensory neurons: a peripheral mechanism of analgesic action. Anesth Analg 2012; 114(2): 442-9.
79. [79] Yang Q, Wu ZZ, Li ZW, Wei JB and Hu QS. Modulation by oxytocin of ATP-activated currents in rat dorsal root ganglion neurons. Neuropharmology 2002; 43: 910-6.
80. [80] Wang YL, Yuan Y, Yang J, et al. The interaction between the oxytocin and pain modulation in headache patients. Neuropeptides 2013; 47: 93-7.
81. [81] Hwang BH, Chang HM, Gu ZH, Suzuki R. C-fos gene expression is increased in the paraventricular hypothalamic nucleus of Sprague-Dawley rats with visceral pain induced by acetic acid without detectable changes of corticotrophin-releasing factor mRNA: a quantitative approach with an image analysis systems. Anat Rec (Hoboken) 2007; 290: 406-13.
82. [82] Alfven G. Plasma oxytocin in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2004; 38: 513-7.
83. [83] Alfven G, de la Torre B, Uvnas-Moberg K. Depressed concentrations of oxytocin and cortisol in children with recurrent abdominal pain of non-organic origin. Acta Paediatr 1994; 83: 1076-80.
84. [84] Anderberg UM, Uvnäs-Moberg K. Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000; 59: 373-9.
85. [85] Grewen KM, Light KC, Mechlin B, Girdler SS. Ethnicity is associated with alterations in oxytocin relationships to pain sensitivity in women. Ethn Health 2008; 13: 219-41.
86. [86] Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. Spine (Phila Pa 1976) 1994; 19: 867-71.
87. [87] Louvel D, Delvaux M, Felez A, et al. Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome. Gut 1996; 39: 741-7.
88. [88] Ohlsson B, Truedsson M, Bengtsson M, Torstenson R, Sjolund K, Bjornsson ES, Simren M. Effects of long-term treatment with oxytocin in chronic constipation; a double-blind, placebo-controlled pilot trial. Neurogastroenterol Motil 2005; 17: 697-704.
89. [89] Singer T, Snozzi R, Bird G, et al. Effects of oxytocin and prosocial behavior on brain responses to direct and vicariously experienced pain. Emotion 2008; 8: 781-91.
90. [90] Uryvaev IuV, Petrov GA. Decreased pain sensitivity in man after treatment with superlow doses of oxytocin. Biull Eksp Biol Med 1996; 122: 487-9.
91. [91] Rash JA, Campbell TS. The effect of intranasal oxytocin administration on acute cold pressor pain: a placebo-controlled, doubleblind, within-subjects crossover trial. Psychosom Med 2014; 76(6): 422-9.
92. [92] Madrazo I, Franco-Bourland R, Leon-Meza V, Mena I. Intraventricular somatostatin-14, arginine vasopressin, and oxytocin: analgesic effect in a patient with intractable cancer pain. Appl Neurophysiol 1987; 50: 427-31.
93. [93] Wotjak CT, Ganster J, Kohl G, Holsboer F, Landgraf R, Engelmann M. Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience 1998; 85: 1209-22.
94. [94] Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004; 25: 150-76.
95. [95] Morin V, Del Castillo JR, Authier S, et al. Evidence for non-linear pharmacokinetics of oxytocin in anesthetized rat. J Pharm Sci 2008; 11: 12-24.
96. [96] Bethlehem RAI, van Honk J, Auyeung B and Baron-Cohen S. Oxytocin, brain physiology and functional connectivity: a review of intranasal oxytocin fMRI studies. Psychoneuroendocrinol 2012; epub Nov 2012.
97. [97] Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-6.
98. Guastella AJ. Hickie IB, McGuinness MM, et al. Recommendations for the standardization of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2012; epub Dec 20.
99. [99] Frasch A, Zetzsche T, Steiger A, Jirikowski GF. Reduction of plasma oxytocin levels in patients suffering from major depression. Adv Exp Med Biol 1995; 395: 257-8.
100. [100] Scantamburlo G, Hansenne M, Fuchs S, et al. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinol 2007; 32: 407-10.
101. [101] Arletti R, Bertolini A. Oxytocin as an antidepressant in two animal models of depression. Life Sci 1987; 41: 1725-30.
102. [102] Uvnäs-Moberg K, Bjökstrand E, Hillegaart V, Ahlenius S. Oxytocin as a possible mediator of SSRI-induced antidepressant effects. Psychopharmacol 1999; 142: 95-101.
103. [103] Yoshida M, Takayanagi Y, Inoue K, et al. Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 2009; 29: 2259-71.
104. [104] Uvnas-Moberg K. Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinol 1998; 23: 819-35.
105. [105] Asmundson GJG, Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety 2009; 26: 888-901.
106. [106] Howell RT, Kern ML, Lyubomirsky S. Health benefits: metaanalytically determining the impact of well-being on objective health outcomes. Health Psychol Rev 2007; 1: 83-136
107. [107] Pressman SD, Cohen S. Does positive affect influence health? Psych Bull 2005; 131: 925-71.
108. [108] Brown DC, Bernier N, Shofer F, Steinberg SA, Perkowski SZ. Effect of intrathecal and intravenous administration of oxytocin on amplitude of the reflex-evoked muscle action potential after electrical stimulation of the tooth pulp in anesthetized dogs. Am J Vet Res 2002; 63: 1354-8.
109. [109] Brown DC, Perkowski S. Oxytocin content of the cerebrospinal fluid of dogs and its relationship to pain induced by spinal cord compression. Vet Surg 1998; 27: 607-11.
110. [110] Blum B and Israeli J. Oxytocin antagonism of hypothalamicinduced angina-like ECG changes and pressor effects in the cat. Experientia 1983; 39: 1349-51.
111. [111] Tallarida G, Baldoni F, Peruzzi G, Brindisi F, Raimondi G and Sangiorgi M. Cardiovascular and respiratory chemoreflexes from the hinidlimb sensory receptors evoked by intra-arterial injection of bradykinin and other chemical agents in the rabbit. J Pharmacol Exp Ther 1979; 208: 319-29.
112. [112] Yu SQ, Lundeberg T, Yu LC. Involvement of oxytocin in spinal antinociception in rats with inflammation. Brain Res 2003; 983: 13-22.
113. [113] Yang J, Pan YJ, Zhao Y, et al. Oxytocin in the rat caudate nucleus influences pain modulation. Peptides 2011; 32: 2104-7.
114. [114] Gu XL, Yu LC. Involvement of opioid receptors in oxytocininduced antinociception in the nucleus accumbens of rats. J Pain 2007; 8: 85-90.
115. [115] Han Y, Yu LC. Involvement of oxytocin and its receptor in nociceptive modulation in the central nucleus of amygdala of rats. Neurosci Lett 2009; 454: 101-4.
116. [116] Arletti R, Benelli A, Bertolini A. Influence of oxytocin on nociception and morphine antinociception. Neuropeptides 1993; 24: 125-9.
117. [117] Uvnas-Moberg K, Alster P, Petersson M, Sohlstrom A and Bjorkstrand E. Postnatal oxytocin injections cause sustained weight gain and increased nociceptive thresholds in male and female rats. Ped Res 1998; 43: 344-8.
118. [118] Uvnas-Moberg K, Bruzelius G, Alster P, Bileviciute I, Lundeberg T. Oxytocin increases and a specific oxytocin antagonist decreases pain threshold in male rats. Acta Physiol Scand 1992; 144: 487-8.
119. [119] Uvnas-Moberg K, Bruzelius G, Alster P, Lundeberg T. The antinociceptive effect of nonnoxious sensory stimulation is mediated partly through oxytocinergic mechanisms. Acta Physiol Scand 1993; 149: 199-204.
120. [120] Gao L, Yu LC. Involvement of opioid receptors in the oxytocininduced antinociception in the central nervous system of rats. Regul Pept 2004; 120: 53-8.
121. [121] Schorscher-Petcu A, Sotocinal S, Ciura S, et al. Oxytocin-induced analgesia and scratching are mediated by the vasopressin-1A receptor in the mouse. J Neurosci 2010; 30: 8274-84.
122. [122] Xu XJ, Wiesenfeld-Hallin Z. Is systemically administered oxytocin an analgesic in rats? Pain 1994; 57: 193-6.
123. [123] Xu XJ, Wiesenfeld-Hallin Z. Intrathecal oxytocin facilitates the spinal nociceptive flexor reflex in the rat. Neuroreport 1994; 5: 750-2.
124. [124] Caldwell HK, Young WS. Oxytocin and Vasopressin: Genetics and Behavioral Implications. In: Lajtha A, Lim R, editors. Handbook of Neurochemistry and Molecular Neurobiology: Springer US.2006; pp. 573-607.
125. [125] Lund I, Yu L-C, Uvnas-Moberg K, et al. Repeated massage-like stimulation induces long-term effects on nociception: contribution of oxytocinergic mechanisms. Eur J Neurosci 2002; 16: 330-8.
126. [126] Petersson M, Wiberg U, Lundeberg T and Uvnas-Moberg, K. Oxytocin decreases carrageenan induced inflammation in rats. Peptides 2001; 22: 1479-84
127. [127] Padhy BM and Kumar VL. Inhibition of Calotropic procera latexiduced inflammatory hyperalgesia oxytocin and melatonin. Mediators of Inflamm 2005; 6: 360-5.
128. [128] Russo R, D-Agostino B, Raso GM, et al. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides 2012; 38: 81-8.
129. [129] Chow LH, Tao PL, Chen JCm Liao RM, Chang EP, Huang EYK. A possible correlation between oxytocin-induced and angiotensive IV-induced anti-hyperalgesia at the spinal leveling rats. Peptides 2013; 39: 21-8.
130. [130] Zubrzycka M, Fichna J, Janecka A. Inhibition of trigeminohypoglossal reflex in rats by oxytocin is mediated by mu and kappa opioid receptors. Brain Res 2005; 1035: 67-72.
131. [131] Condes-Lara M, Maie IA, Dickenson AH. Oxytocin actions on afferent evoked spinal cord neuronal activities in neuropathic but not in normal rats. Brain Res 2005; 1045: 124-33.
132. [132] Gutierrez S, Liu B, Hayashida K-I, Houle TT and Eisenach JC. Reversal of peripheral nerve injury-induced hypersensitivity in the postpartum period: role of spinal oxytocin. Anesthesiol 2013; 118: 152-9.
133. [133] Kang YS and Park JH. Brain uptake and the analgesic effect of oxytocin-its usefulness as an analgesic agent. Arch Pharm Res 2000; 23: 391-5.
134. [134] Schorscher-Petcu A, Dupre A and Tribollet E. Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset. Neurosci Letts 2009; 461: 217-22.
135. [135] Rojas-Piloni G, Mejia-Rodriguez R, Martinez-Lorenzana G, Condes-Lara M. Oxytocin, but not vassopressin, modulates nociceptive responses in dorsal horn neurons. Neurosci Lett 2010; 476: 32-5.
136. [136] Yimiya R, Ben-Eliyahu, Shauvit Y, Marek P and Liebeskind JC. Stimulation of the hypothalamic paraventricular nucleus produces analgesia not mediated by vasopressin or endogenous opioids. Brain Res 1990; 537: 169-74.
137. [137] Yang J, Liang JY, Zhang XY, et al. Oxytocin, but not arginine vasopressin is involving in the antinociceptive role of hypothalamic supraoptic nucleus. Peptides 2011; 32: 1042-6.
138. [138] Lundeberg T, Meister B, Bjorkstrand E and Uvnas-Moberg K. Oxytocin modulates the effects of galanin in carrageenan-induced hyperalgesia in rats. Brain Res 1993; 608: 181-5.
139. [139] Lundeberg T, Uvnas-Moberg K, Agren G, Bruzelius G. Antinociceptive effects of oxytocin in rats and mice. Neurosci Lett 1994; 170: 153-7.
140. [140] Petersson M, Eklund M, Uvnas-Moberg K. Oxytocin decreases corticosterone and nociception and increases motor activity in OVX rats. Maturitas 2005; 51: 426-33.
141. [141] Agren G, Uvnas-Moberg K, Lundeberg T. Olfactory cues from an oxytocin-injected male rat can induce anti-nociception in its cagemates. Neuroreport 1997; 8: 3073-6.
142. [142] Martinez-Lorenzana G, Espinosa-Lopez L, Carranza M, et al. PVN electrical stimulation prolongs withdrawal latencies and releases oxytocin in cerebrospinal fluid, plasma, and spinal cord tissue in intact and neuropathic rats. Pain 2008; 140: 265-73.
143. [143] Miranda-Cardenas Y, Rojas-Piloni G, Martinez-Lorenzana G, et al. Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. Pain 2006; 122: 182-9.
144. [144] Rinaman L. Visceral sensory inputs to the endocrine hypothalamus. Front Neuroendocrinol 2007: 28: 50-60.
145. [145] Condes-Lara M, Gonzalez NM, Martinez-Lorenzana G, Delgado OL, Freund-Mercier MJ. Actions of oxytocin and interactions with glutamate on spontaneous and evoked dorsal spinal cord neuronal activities. Brain Res 2003; 976: 75-81.
146. [146] Swanson LW, McKellar S. The distribution of oxytocin-and neurophysin-stained fibers in the spinal cord of the rat and monkey. J Comp Neurol 1979; 188: 87-106.
147. Moreno-Lopez Y, Martinez-Lorenzana G, Condes-Lara M and Rojas-Piloni G. Identification of oxytocin receptor in the dorsal horn and nociceptive dorsal root ganglion neurons. Neuropeptides 2012; epub Oct 24.
148. [148] Breton JD, Veinante P, Uhl-Bronner S, et al. Oxytocin-induced antinociception in the spinal cord is mediated by a subpopulation of glutamatergic neurons in lamina I-II which amplify GABAergic inhibition. Mol Pain 2008; 4: 19.
149. [149] Breton JD, Poisbeau P, Darbon P. Antinociceptive action of oxytocin involves inhibition of potassium channel currents in lamina II neurons of the rat spinal cord. Mol Pain 2009; 5: 63.
150. [150] DeLaTorre S, Rojas-Piloni G, Martinez-Lorenzana G, Rodriguez-Jimenez J, Villanueva L, Condes-Lara M. Paraventricular oxytocinergic hypothalamic prevention or interruption of long-term potentiation in dorsal horn nociceptive neurons: electrophysiological and behavioral evidence. Pain 2009; 144: 320-8.
151. [151] Rojas-Piloni G, Martinez-Lorenzana G, DelaTorre S, Condes-Lara M. Nociceptive spinothalamic tract and postsynaptic dorsal column neurons are modulated by paraventricular hypothalamic activation. Eur J Neurosci 2008; 28: 546-58.
152. [152] Condes-Lara M, Rojas-Piloni G, Martinez-Lorenzana G, et al. Paraventricular hypothalamic influences on spinal nociceptive processing. Brain Res 2006; 1081: 126-37
153. [153] Rojas-Piloni G, Lopez-Hidalgo M, Martinez-Lorenzana G, Rodriguez-Jimenez J, Condes-Lara M. GABA-mediated oxytocinergic inhibition in dorsal horn neurons by hypothalamic paraventricular nucleus stimulation. Brain Res 2007; 1137: 69-77.
154. [154] Condes-Lara M, Rojas-Piloni G, Martinez-Lorenzana G, Lopez-Hidalgo M, Rodriguez-Jimenez J. Hypothalamospinal oxytocinergic antinociception is mediated by GABAergic and opiate neurons that reduce A-delta and C fiber primary afferent excitation of spinalcord cells. Brain Res 2009; 1247: 38-49.
155. [155] Black LV, Ness TJ, Robbins MT. Effects of oxytocin and prolactin on stress-induced bladder hypersensitivity in female rats. J Pain 2009; 10: 1065-72.
156. [156] Engle MP, Ness TJ, Robbins MT. Intrathecal oxytocin inhibits visceromotor reflex and spinal neuronal responses to noxious distention of the rat urinary bladder. Reg Anesth Pain Med. 2012; 37: 515-20.
157. [157] MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011; 36(8): 1114-26.